Zollinger-Ellison syndrome other imaging findings: Difference between revisions
| Line 10: | Line 10: | ||
==Gallery== | ==Gallery== | ||
<gallery widths=200px> | <gallery widths=200px> | ||
SRS1.jpg|37-year-old male with MEN 1. The patient was injected with 6.4 mCi In-111 octreotide, and images were acquired in the anterior and posterior projections at 4 hours.Findings are consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes either in the peripancreatic or porta hepatis region.<ref | SRS1.jpg|37-year-old male with MEN 1. The patient was injected with 6.4 mCi In-111 octreotide, and images were acquired in the anterior and posterior projections at 4 hours.Findings are consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes either in the peripancreatic or porta hepatis region.<ref name= The role of nuclear imaging in multiple endocrine neoplasia 1 (MEN 1)"HarveyPasieka2012">{{cite journal|last1=Harvey|first1=Adrian|last2=Pasieka|first2=Janice L.|last3=Al-Bisher|first3=Hassan|last4=Dixon|first4=Elijah|title=Primary Hepatic Gastrinoma Causing Zollinger-Ellison Syndrome: A Rare and Challenging Diagnosis|journal=Cancers|volume=4|issue=4|year=2012|pages=130–140|issn=2072-6694|doi=10.3390/cancers4010130}}</ref> | ||
SRS2.jpg|37-year-old male with MEN 1. The patient was injected with 6.4 mCi In-111 octreotide, and images were acquired in the anterior and posterior projections at 24 hours. Findings are consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes either in the peripancreatic or porta hepatis region.<ref | SRS2.jpg|37-year-old male with MEN 1. The patient was injected with 6.4 mCi In-111 octreotide, and images were acquired in the anterior and posterior projections at 24 hours. Findings are consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes either in the peripancreatic or porta hepatis region.<ref name= The role of nuclear imaging in multiple endocrine neoplasia 1 (MEN 1)"HarveyPasieka2012">{{cite journal|last1=Harvey|first1=Adrian|last2=Pasieka|first2=Janice L.|last3=Al-Bisher|first3=Hassan|last4=Dixon|first4=Elijah|title=Primary Hepatic Gastrinoma Causing Zollinger-Ellison Syndrome: A Rare and Challenging Diagnosis|journal=Cancers|volume=4|issue=4|year=2012|pages=130–140|issn=2072-6694|doi=10.3390/cancers4010130}}</ref> | ||
SRS3.jpg|Axial scan at 24 hours.<ref | SRS3.jpg|Axial scan at 24 hours.<ref name= The role of nuclear imaging in multiple endocrine neoplasia 1 (MEN 1)"HarveyPasieka2012">{{cite journal|last1=Harvey|first1=Adrian|last2=Pasieka|first2=Janice L.|last3=Al-Bisher|first3=Hassan|last4=Dixon|first4=Elijah|title=Primary Hepatic Gastrinoma Causing Zollinger-Ellison Syndrome: A Rare and Challenging Diagnosis|journal=Cancers|volume=4|issue=4|year=2012|pages=130–140|issn=2072-6694|doi=10.3390/cancers4010130}}</ref> | ||
SRS4.jpg|Coronal scan at 24 hours.<ref | SRS4.jpg|Coronal scan at 24 hours.<ref name= The role of nuclear imaging in multiple endocrine neoplasia 1 (MEN 1)"HarveyPasieka2012">{{cite journal|last1=Harvey|first1=Adrian|last2=Pasieka|first2=Janice L.|last3=Al-Bisher|first3=Hassan|last4=Dixon|first4=Elijah|title=Primary Hepatic Gastrinoma Causing Zollinger-Ellison Syndrome: A Rare and Challenging Diagnosis|journal=Cancers|volume=4|issue=4|year=2012|pages=130–140|issn=2072-6694|doi=10.3390/cancers4010130}}</ref> | ||
==References== | ==References== | ||
Revision as of 13:27, 2 October 2015
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome other imaging findings On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome other imaging findings |
|
Zollinger-Ellison syndrome other imaging findings in the news |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Endoscopic ultrasound and Somatostatin receptor scintigraphy (SRS) (octreotide scan) may be helpful in the diagnosis of Zollinger-Ellison syndrome caused by gastrinoma.[1]
Other Imaging Findings
Other imaging studies that may be helpful in the diagnosis of Zollinger-Ellison syndrome include:
- Endoscopic ultrasound[1]
- Somatostatin receptor scintigraphy (SRS) (octreotide scan)[2]
Gallery
<gallery widths=200px>
SRS1.jpg|37-year-old male with MEN 1. The patient was injected with 6.4 mCi In-111 octreotide, and images were acquired in the anterior and posterior projections at 4 hours.Findings are consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes either in the peripancreatic or porta hepatis region.Invalid parameter in <ref> tag
SRS2.jpg|37-year-old male with MEN 1. The patient was injected with 6.4 mCi In-111 octreotide, and images were acquired in the anterior and posterior projections at 24 hours. Findings are consistent with metastatic somatostatin-receptor-positive malignancy involving the lymph nodes either in the peripancreatic or porta hepatis region.Invalid parameter in <ref> tag
SRS3.jpg|Axial scan at 24 hours.Invalid parameter in <ref> tag
SRS4.jpg|Coronal scan at 24 hours.Invalid parameter in <ref> tag
References
- ↑ 1.0 1.1 Tang, Shou-jiang; Wu, Ruonan; Bhaijee, Feriyl (2014). "Zollinger–Ellison Syndrome". Video Journal and Encyclopedia of GI Endoscopy. 1 (3–4): 666–668. doi:10.1016/j.vjgien.2013.06.005. ISSN 2212-0971.
- ↑ Cadiot G, Bonnaud G, Lebtahi R, Sarda L, Ruszniewski P, Le Guludec D; et al. (1997). "Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE)". Gut. 41 (1): 107–14. PMC 1027237. PMID 9274481.